Tissue | Expression Dynamics | Abbreviation |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007189713 | Endometrium | EEC | DNA biosynthetic process | 39/2168 | 180/18723 | 7.68e-05 | 1.11e-03 | 39 |
GO:004578713 | Endometrium | EEC | positive regulation of cell cycle | 59/2168 | 313/18723 | 1.04e-04 | 1.44e-03 | 59 |
GO:000301213 | Endometrium | EEC | muscle system process | 79/2168 | 452/18723 | 1.16e-04 | 1.55e-03 | 79 |
GO:19007451 | Endometrium | EEC | positive regulation of p38MAPK cascade | 12/2168 | 32/18723 | 1.37e-04 | 1.78e-03 | 12 |
GO:190122411 | Endometrium | EEC | positive regulation of NIK/NF-kappaB signaling | 19/2168 | 69/18723 | 2.27e-04 | 2.70e-03 | 19 |
GO:007135615 | Endometrium | EEC | cellular response to tumor necrosis factor | 45/2168 | 229/18723 | 2.54e-04 | 2.94e-03 | 45 |
GO:003320912 | Endometrium | EEC | tumor necrosis factor-mediated signaling pathway | 24/2168 | 99/18723 | 3.12e-04 | 3.47e-03 | 24 |
GO:005109013 | Endometrium | EEC | regulation of DNA-binding transcription factor activity | 75/2168 | 440/18723 | 3.71e-04 | 3.97e-03 | 75 |
GO:003461215 | Endometrium | EEC | response to tumor necrosis factor | 48/2168 | 253/18723 | 3.77e-04 | 4.03e-03 | 48 |
GO:001821013 | Endometrium | EEC | peptidyl-threonine modification | 28/2168 | 125/18723 | 4.23e-04 | 4.42e-03 | 28 |
GO:001810713 | Endometrium | EEC | peptidyl-threonine phosphorylation | 26/2168 | 116/18723 | 6.60e-04 | 6.37e-03 | 26 |
GO:007030113 | Endometrium | EEC | cellular response to hydrogen peroxide | 23/2168 | 98/18723 | 6.72e-04 | 6.47e-03 | 23 |
GO:009006812 | Endometrium | EEC | positive regulation of cell cycle process | 44/2168 | 236/18723 | 9.39e-04 | 8.42e-03 | 44 |
GO:003287411 | Endometrium | EEC | positive regulation of stress-activated MAPK cascade | 27/2168 | 126/18723 | 1.09e-03 | 9.43e-03 | 27 |
GO:007030411 | Endometrium | EEC | positive regulation of stress-activated protein kinase signaling cascade | 27/2168 | 128/18723 | 1.39e-03 | 1.14e-02 | 27 |
GO:00069361 | Endometrium | EEC | muscle contraction | 59/2168 | 347/18723 | 1.57e-03 | 1.26e-02 | 59 |
GO:19012222 | Endometrium | EEC | regulation of NIK/NF-kappaB signaling | 24/2168 | 112/18723 | 2.00e-03 | 1.51e-02 | 24 |
GO:004593113 | Endometrium | EEC | positive regulation of mitotic cell cycle | 25/2168 | 121/18723 | 2.76e-03 | 1.97e-02 | 25 |
GO:009025712 | Endometrium | EEC | regulation of muscle system process | 44/2168 | 252/18723 | 3.51e-03 | 2.36e-02 | 44 |
GO:000181913 | Endometrium | EEC | positive regulation of cytokine production | 73/2168 | 467/18723 | 4.64e-03 | 2.97e-02 | 73 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0407116 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa006003 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa0407117 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa0515212 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa04666110 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa0060012 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa040718 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
hsa0466610 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
hsa00600 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa0407111 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
hsa006001 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa0407114 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa0466618 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
hsa04370 | Oral cavity | OSCC | VEGF signaling pathway | 37/3704 | 59/8465 | 2.53e-03 | 6.62e-03 | 3.37e-03 | 37 |
hsa006002 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0407115 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPHK1 | SNV | Missense_Mutation | rs149492135 | c.1055N>T | p.Ser352Leu | p.S352L | Q9NYA1 | protein_coding | deleterious(0) | possibly_damaging(0.755) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
SPHK1 | deletion | Frame_Shift_Del | | c.290_303delTCCCGCGGCCCTGC | p.Leu97ProfsTer29 | p.L97Pfs*29 | Q9NYA1 | protein_coding | | | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SPHK1 | SNV | Missense_Mutation | rs866618568 | c.812N>A | p.Arg271Gln | p.R271Q | Q9NYA1 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SPHK1 | SNV | Missense_Mutation | | c.961G>C | p.Asp321His | p.D321H | Q9NYA1 | protein_coding | deleterious(0.03) | possibly_damaging(0.847) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SPHK1 | SNV | Missense_Mutation | novel | c.510G>A | p.Met170Ile | p.M170I | Q9NYA1 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SPHK1 | deletion | Frame_Shift_Del | | c.1160delG | p.Arg387ProfsTer44 | p.R387Pfs*44 | Q9NYA1 | protein_coding | | | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | rs773839692 | c.1133N>T | p.Ala378Val | p.A378V | Q9NYA1 | protein_coding | deleterious(0) | benign(0.325) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | rs775563147 | c.255N>T | p.Glu85Asp | p.E85D | Q9NYA1 | protein_coding | tolerated(0.08) | benign(0.06) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | novel | c.713N>C | p.Leu238Pro | p.L238P | Q9NYA1 | protein_coding | deleterious(0) | possibly_damaging(0.637) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPHK1 | SNV | Missense_Mutation | novel | c.1220N>G | p.Tyr407Cys | p.Y407C | Q9NYA1 | protein_coding | tolerated(0.1) | benign(0.047) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-11 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | ABC294640 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | inhibitor | 404859088 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-13 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | GSK618334 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | inhibitor | 178103235 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-16 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | PMID27539678-Compound-7 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | inhibitor | 381744899 | | |
8877 | SPHK1 | ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOME | | Methylbenzenesulfonamide derivative 1 | | |